about
Unsung Hero Robert C. GalloCalculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohortFrom pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients.German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients.IL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infectionSafety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection.Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.Gene therapy strategies: can we eradicate HIV?Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progressionComprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.Functional characterization of HLA-G⁺ regulatory T cells in HIV-1 infection.Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapyLow SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1.Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCGHIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008Expansion of HIV-specific T follicular helper cells in chronic HIV infection.Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapyImpact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsBrief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype.How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.Treatment of heavily antiretroviral-experienced HIV-infected patients.Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsVirological rebound and its consequences during treatment interruption.International AIDS Society global scientific strategy: towards an HIV cure 2016.Incidence of abacavir hypersensitivity reactions in euroSIDA.Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report.Linker-Region Modified Derivatives of the Deoxyhypusine Synthase Inhibitor CNI-1493 Suppress HIV-1 Replication.Patient-adapted, specific activation of HIV-1 by customized TAL effectors (TALEs), a proof of principle study.Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon.Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.Stereoselective synthesis of D- and L-carbocyclic nucleosides by enzymatically catalyzed kinetic resolution.Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .High HIV prevalence among children presenting for general consultation in rural Cameroon.
P50
Q22065525-E5297C25-684B-43F7-A556-DBFB6310FA11Q28477027-419FA6D8-6B18-4E74-BF35-4D0DEE7AB062Q30925594-1E2BBF03-938F-4157-B880-316EE87A4247Q32054802-0A31CC84-88D5-44EF-B9CD-F9127D782F1FQ33608661-572BC61B-333D-4E39-819D-325138C48002Q33863006-0174E284-AC36-4400-8140-EBDE3DAA4D57Q33882890-847A51CC-F046-4817-BB77-42E1D41C7EFAQ33915350-0AB4A8A8-9F34-40DD-9864-6ECEA785B09BQ34078508-0BD125F5-DAD3-4EC1-8204-F59CDE2C045DQ34165454-ECBA4269-F46C-461D-B3B1-AE84E9579027Q34413527-AD25D90A-1442-4268-AF2F-EC3783B769E4Q34450282-FE218C2D-ED60-46A8-A074-A71911976FA7Q34487847-72E4E526-1752-4A2A-9D5D-68861948485BQ34574856-45AC4EC5-77FB-4580-B660-A9EE4B687F02Q35088585-0FDD7AD7-6705-44B9-AAA4-76EE4012C851Q35126450-1E7F5181-C401-4B8A-9772-A3C2A0A612A3Q35842343-4A36D181-F38C-4181-B061-954F1663C099Q35958548-C809AEDF-2B42-4EE3-B9D3-19D027D4B928Q36190755-4FCE2729-CBB4-4C6A-B27C-16A11A90B85CQ36375293-B4F200E4-1282-436C-8DCD-9003514BA2F4Q36400457-40E6D50B-1105-48CF-BC41-6AC66447438BQ36682506-C3CE116C-8E92-4A24-B782-5B8C4C008E77Q36721002-7943D146-E284-4FCE-A661-95889F1EC159Q36810593-ED86EB5E-4BBE-4527-90EA-1C5F91F69731Q36969737-E2FDA881-A6FB-4B97-B80A-1FAF5377C407Q37064900-A532663A-1A2F-499F-B5B2-3C1969D16584Q37273652-DF417EF0-0CCB-472B-9C52-54F8A6FE18B6Q37447104-5DAD76BD-C06A-4ED6-B15E-9A433B56645CQ37661770-74AA30C4-B570-43BA-AEDD-F6CDB0F991D7Q38454531-D3439A80-BE1F-4EB7-AF73-21C014B2A040Q38615613-E446043C-4002-464B-B322-4A6C13B27F7CQ38806965-0A041914-C980-4388-9DDE-A8F48475F911Q38952763-C557C609-2BEA-4839-9780-92BE4985C779Q38990744-B41BF9B4-6921-41A3-BC4B-8F9BED650122Q39001683-8A36FCD2-C1EE-4871-9070-1D4C8AF5AAADQ39251042-93BB9953-E04F-429A-97FB-03A78101E1F6Q39308672-3B3FFB7C-5356-4239-A738-6266D499D84BQ39437108-BCD2C767-4A9F-44F6-88F7-F55F0073A52FQ39633946-2B37D281-F8DE-4191-B2D2-32914ED10C45Q39633951-0F676B8A-D6F9-4212-AAE8-08317471A098
P50
name
Jan van Lunzen
@ast
Jan van Lunzen
@en
Jan van Lunzen
@es
Jan van Lunzen
@fr
Jan van Lunzen
@nl
type
label
Jan van Lunzen
@ast
Jan van Lunzen
@en
Jan van Lunzen
@es
Jan van Lunzen
@fr
Jan van Lunzen
@nl
prefLabel
Jan van Lunzen
@ast
Jan van Lunzen
@en
Jan van Lunzen
@es
Jan van Lunzen
@fr
Jan van Lunzen
@nl